Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch

Value-Added Medicines Developer Quietly Reframes 30-Asset Goal

Executive Summary

Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.

You may also be interested in...



Hyloris Announces Approval Of Condylox First Generic

Hyloris has received US approval for its generic podofilox gel, previously referred to as HY-016.

Hyloris Submits Additional Data For Maxigesic IV Filing To US FDA

Hyloris has submitted additional data to the US Food and Drug Administration about its value-added analgesic Maxigesic IV, following enquiries about potential extractable and leachable compounds expected to be present in the product due to the packaging.

Hyloris Ramps Up Product Expansion With New Idiopathic Rhinitis Spray

Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel